Nicholas Iannotti
Overview
Explore the profile of Nicholas Iannotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2024 Mar;
4(3):785.
PMID: 38477691
No abstract available.
2.
Munster P, Iannotti N, Cho D, Kirkwood J, Villaruz L, Gibney G, et al.
Cancer Res Commun
. 2023 Dec;
3(12):2572-2584.
PMID: 38115208
Purpose: This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ inhibitor) in combination with...
3.
Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor M, et al.
Future Oncol
. 2022 Feb;
18(11):1333-1342.
PMID: 35144482
This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Patients receiving >2 years of avelumab were...
4.
Ramalingam S, Thara E, Awad M, Dowlati A, Haque B, Stinchcombe T, et al.
Cancer
. 2021 Sep;
128(1):65-74.
PMID: 34478166
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors may synergize with programmed cell death receptor-1 (PD-1) inhibitors to enhance adaptive and innate antitumor immune responses. In the phase 2 JASPER study (NCT04475939), the...
5.
Verschraegen C, Jerusalem G, McClay E, Iannotti N, Redfern C, Bennouna J, et al.
J Immunother Cancer
. 2020 Sep;
8(2).
PMID: 32907924
Introduction: Avelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, and in combination with axitinib for advanced...
6.
Kelly K, Infante J, Taylor M, Patel M, Wong D, Iannotti N, et al.
Cancer
. 2018 Feb;
124(9):2010-2017.
PMID: 29469949
Background: Antibodies targeting the programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) checkpoint may cause adverse events (AEs) that are linked to the mechanism of action of this therapeutic...
7.
Gulley J, Rajan A, Spigel D, Iannotti N, Chandler J, Wong D, et al.
Lancet Oncol
. 2017 Apr;
18(5):599-610.
PMID: 28373005
Background: Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety...
8.
Chan A, Delaloge S, Holmes F, Moy B, Iwata H, Harvey V, et al.
Lancet Oncol
. 2016 Feb;
17(3):367-377.
PMID: 26874901
Background: Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of...
9.
Vahdat L, Garcia A, Vogel C, Pellegrino C, Lindquist D, Iannotti N, et al.
Breast Cancer Res Treat
. 2013 Jul;
140(2):341-51.
PMID: 23877339
Peripheral neuropathy is a common toxicity associated with tubulin-targeted chemotherapeutic agents. This Phase II study compares the incidence and severity of neuropathy associated with eribulin mesylate or ixabepilone in metastatic...
10.
Mitchell E, Piperdi B, Lacouture M, Shearer H, Iannotti N, Pillai M, et al.
Clin Colorectal Cancer
. 2011 Oct;
10(4):333-9.
PMID: 22000810
Background: Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS...